RT Journal Article
SR Electronic
T1 Cognitive impairment is a common comorbidity in COVID-19 deceased patients. A hospital-based retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.08.20125872
DO 10.1101/2020.06.08.20125872
A1 Martín-Jiménez, Paloma
A1 Muñoz-García, Mariana I.
A1 Seoane, David
A1 Roca-Rodríguez, Lucas
A1 García-Reyne, Ana
A1 Lalueza, Antonio
A1 Maestro, Guillermo
A1 Folgueira, Dolores
A1 Blanco-Palmero, Víctor A.
A1 Martín, Alejandro Herrero-San
A1 Llamas-Velasco, Sara
A1 Pérez-Martínez, David A.
A1 González-Sánchez, Marta
A1 Villarejo-Galende, Alberto
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.08.20125872.abstract
AB Introduction Little is known about the relation of cognitive impairment (CI) to COVID-19 mortality. Here, we analyse the frequency of CI in deceased COVID-19 patients.Methods We included 477 adult cases that died after admission from March 1 to March 31, 2020: 281 with confirmed COVID-19, 58 probable COVID-19, and 138 who died of other causes.Results The number of comorbidities was high in the confirmed COVID-19, and CI was common (30%: 21.1% dementia; 8.9% mild cognitive impairment). Subjects with CI were older, more lived in nursing homes and had shorter times from symptom onset to death than those without CI. COVID-19 patients with CI were rarely admitted to the ICU and fewer received non-invasive mechanical ventilation, but palliative care was provided more often.Conclusions Dementia is a frequent comorbidity in COVID-19 deceased patients. The burden of COVID-19 in the dementia community will be high.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Victor Blanco-Palmero is supported by the Instituto de Salud Carlos III (ISCIII; Spanish Biomedical Research Institute) thorough a Rio Hortega contract (CM 18/00095). Dr. Sara Llamas-Velasco is supported by the Instituto de Salud Carlos III (ISCIII; Spanish Biomedical Research Institute) thorough a Juan Rodes contract (JR 18/00046). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed and approved by the local ethics committee / institutional review board (EC/IRB).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized data may be available upon reasonable request from qualified researchers.